Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Meet Our People

Our employees are passionate, innovative, and collaborative. Together, we strive to relieve suffering for people with great needs, but few options.

The Impact of TD

Tardive dyskenisia (TD) is estimated to affect approximately 600,000 people in the U.S. Although it can look or feel different from day to day, TD is a chronic condition and symptoms may be persistent.

Q2 2022 Financial Results

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) financial results for the second quarter ended June 30, 2022 and reiterated financial guidance for 2022.